Successful treatment of multicentric castleman's disease with bilateral orbital tumour using rituximab

Ide, Makoto; Ogawa, Eiichi; Kasagi, Kanji; Kawachi, Yasunori; Ogino, Tetsuro

doi:10.1046/j.1365-2141.2003.04358.x

Cited by 28 publications

(12 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Combination chemotherapies, including cyclophosphamide, vincristine and prednisolone, and cyclophosphamide, adriamycin, vincristine and prednisolone, induced a complete response in approximately 50% of patients; however, relapses are common [3,4]. Rituximab has also been reported to be effective for MCD in some case reports [18,19,20]. Ocio et al [20 ]reported success with rituximab in immune-related disorders including AIHA and Raynaud’s phenomenon in MCD.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

Yuzuriha¹,

Saitoh²,

Koiso³

et al. 2011

Acta Haematol

View full text Add to dashboard Cite

We describe herein the successful treatment of severe autoimmune hemolytic anemia (AIHA) in a patient with multicentric Castleman disease (MCD) by humanized anti-interleukin-6 (IL-6) receptor antibody (tocilizumab) therapy. Inflammatory anemia is commonly reported; however, AIHA is a very rare complication of MCD. In 1996, a 45-year-old Japanese woman was referred to our hospital because of generalized lymphadenopathy, anemia and skin eruptions. Lymph node biopsy demonstrated MCD. She was treated with prednisolone (1 mg/kg/day), which improved the anemia and skin eruptions. In 2009, she suddenly developed Coombs-positive hemolytic anemia. The blood count was as follows: hemoglobin 4.7 g/dl, platelets 490 × 10⁹/l and white blood cell count 9.8 × 10⁹/l. Both direct and indirect Coombs’ tests were strongly positive. She was treated with 8 mg/kg tocilizumab every 2 weeks. One month later, her hemoglobin levels rose dramatically to 10.9 g/dl and her haptoglobin level, hypergammaglobulinemia and clinical symptoms had also markedly improved. To the best of our knowledge, this is the first report of the efficacy of tocilizumab in AIHA associated with MCD. The well-established role of IL-6 in the pathogenesis of MCD may have been responsible for the improvement in the AIHA associated with MCD. Anti-IL-6 receptor antibody treatment could be an attractive therapeutic approach for AIHA associated with MCD.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

Yuzuriha¹,

Saitoh²,

Koiso³

et al. 2011

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Thus, in five out of 7 patients, rituximab was able to induce a complete remission, which was sustained for more than 6 months in 3 of them. To the best of our knowledge, only two HIV-negative patients with MCD treated with rituximab have been reported [19,20]. One patient's case was associated with advanced systemic amyloidosis and was treated with the combination of cyclophosphamide, prednisone, and rituximab, achieving partial remission but dying 2 months later because of organ complications from amyloidosis.…”

Section: Discussionmentioning

confidence: 99%

“…Some reports of its efficacy in MCD have been published [18][19][20][21][22]. Moreover, it is also increasingly used in immune hemolytic anemia and other immune-related disorders [23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena

et al. 2005

View full text Add to dashboard Cite

Multicentric Castleman disease (MCD) is an uncommon lymphoproliferative disorder for which the best therapeutic option is not yet well established. Immune-related disorders are rare complications of MCD. We report on an MCD case in a 23-year-old patient with extensive abdominal involvement and associated immune hemolytic anemia and Raynaud phenomenon. He was negative for human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8). After 8 courses of the anti-CD20 monoclonal antibody (rituximab), the patient achieved complete remission. Interestingly, Raynaud phenomenon disappeared under treatment and no new hemolytic events occurred. Anti-CD20 antibody treatment could be an attractive therapeutic approach for MCD, mainly when immune-related disorders are associated. Am.

show abstract

“…Choroidal biopsy proved useful because it allowed the oncologist flexibility to choose therapy with a lowside-effect profile. 4 If instead choroidal biopsy had shown malignancy, then combination chemotherapy (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone) might have been more appropriate. 5.…”

Section: Discussionmentioning

confidence: 99%

Multicentric Castleman Disease With Ocular Involvement: A Clinicopathologic Case Report

Emerson¹,

Loriaux²,

Yassin³

et al. 2009

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

show abstract

Successful treatment of multicentric castleman's disease with bilateral orbital tumour using rituximab

Cited by 28 publications

References 4 publications

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

Successful Treatment of Autoimmune Hemolytic Anemia Associated with Multicentric Castleman Disease by Anti-Interleukin-6 Receptor Antibody (Tocilizumab) Therapy

Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena

Multicentric Castleman Disease With Ocular Involvement: A Clinicopathologic Case Report

Contact Info

Product

Resources

About